IP Library › Granted Patent US 12,030,928
Granted Patent B2
US 12,030,928 · App. 17/569,253 · Granted Jul 9, 2024

Anti-influenza B virus neuraminidase antibodies and uses thereof

Inventors: Peter Palese (New York, NY); Florian Krammer (New York, NY); Teddy John Wohlbold (New York, NY); Adolfo Garcia-Sastre (New York, NY)
Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
C07K16/1018A61P31/16G01N33/56983A61K38/00A61K2039/507C07K2317/33C07K2317/34C07K2317/52C07K2317/55C07K2317/565C07K2317/732C07K2317/76C07K2317/94G01N2333/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,030,928
App. No.
17/569,253
Granted
Jul 9, 2024
Kind
B2
Abstract

Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

Claims (34)

1. An isolated polynucleotide sequence comprising a nucleotide sequence encoding an antibody that binds to a neuraminidase (NA) of an influenza B virus strain, wherein the antibody comprises: (i) a variable heavy chain region complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 67, (ii) a variable heavy chain region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, (iii) a variable heavy chain region CDR3 comprising the amino acid sequence of SEQ ID NO: 69, (iv) a variable light chain region complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 70, (v) a variable light chain region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and (vi) a variable light chain region CDR3 comprising the amino acid sequence of SEQ ID NO: 72.

2. An isolated polynucleotide sequence encoding an antibody that binds to a neuraminidase (NA) of an influenza B virus strain, wherein the antibody comprises:

a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 65 and a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 66.

3. An expression vector comprising the polynucleotide sequence of claim 1 .

4. The expression vector of claim 3 , wherein the polynucleotide sequence is operably linked to one or more regulatory regions.

5. An isolated host cell comprising the polynucleotide sequence of claim 1 .

6. An isolated host cell comprising the expression vector of claim 3 .

7. An isolated host cell comprising:

(a) (I) a polynucleotide encoding a heavy chain variable region comprising a heavy chain variable region complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 67, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a heavy variable chain region CDR3 comprising the amino acid sequence of SEQ ID NO: 69; and (II) a polynucleotide encoding a light chain variable region comprising a light chain variable region complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 70, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or

(b) (I) a polynucleotide encoding a heavy chain variable region that is at least 95% identical to the amino acid sequence of SEQ ID NO: 65, wherein the variable heavy chain region comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 69; and (II) a polynucleotide encoding a light chain variable region that is at least 95% identical to the amino acid sequence of SEQ ID NO: 66, wherein the light chain variable region comprises a variable light chain region CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or

(c) (I) a first expression vector comprising a polynucleotide encoding a heavy chain variable region comprising a heavy chain variable region complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 67, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 69; and (II) a second expression vector comprising a polynucleotide encoding a light chain variable region comprising a light chain variable region complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 70, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or

(d) (I) a first expression vector comprising a polynucleotide encoding a heavy chain variable region that is at least 95% identical to the amino acid sequence of SEQ ID NO: 65, wherein the heavy chain variable region comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 69; and (II) a second expression vector comprising a polynucleotide encoding a light chain variable region that is at least 95% identical to the amino acid sequence of SEQ ID NO: 66, wherein the light chain variable region comprises a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 72.

8. An isolated host cell expressing the antibody encoded by the polynucleotide of claim 1 .

9. The isolated host cell of claim 7 , wherein the isolated host cell comprises:

(a) a first expression vector comprising a polynucleotide encoding a variable heavy chain region that is at least 95% identical to the amino acid sequence of SEQ ID NO: 65, wherein the variable heavy chain region comprises a variable heavy chain region CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a variable heavy chain region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a variable heavy chain region CDR3 comprising the amino acid sequence of SEQ ID NO: 69; and

(b) a second expression vector comprising a polynucleotide encoding a variable light chain region that is at least 95% identical to the amino acid sequence of SEQ ID NO: 66, wherein the variable light chain region comprises a variable light chain region CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a variable light chain region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a variable light chain region CDR3 comprising the amino acid sequence of SEQ ID NO: 72.

10. The isolated host cell of claim 7 , wherein the first and second expression vectors each comprise one or more regulatory regions operably linked to the polynucleotide.

11. An isolated host cell engineered to express the antibody encoded by the polynucleotide of claim 2 .

12. A method for expressing an antibody the method, comprising:

(a) culturing the isolated host cell of claim 5 , and

(b) isolating the antibody from the isolated host cell or cell culture.

13. The polynucleotide of claim 2 , wherein the heavy chain variable region comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 69; and the light chain variable region comprises a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 72.

14. The polynucleotide of claim 13 , wherein polynucleotide comprises a nucleotide sequence at least 95% identical to the sequence of SEQ ID NO: 89 and a nucleotide sequence at least 95% identical to the sequence of SEQ ID NO: 90.

15. The polynucleotide of claim 1 , which is cDNA or RNA.

16. The polynucleotide of claim 1 , wherein the antibody is a humanized or chimeric antibody.

17. The polynucleotide of claim 1 , wherein the antibody is scFv, Fab, F(ab′)2 or sdFv.

18. The polynucleotide of claim 1 , wherein the antibody is an IgG.

19. The polynucleotide of claim 13 , which is cDNA or RNA.

20. The polynucleotide of claim 13 , wherein the antibody is a humanized or chimeric antibody.

21. The polynucleotide of claim 13 , wherein the antibody is scFv, Fab, F(ab′)2 or sdFv.

22. The polynucleotide of claim 13 , wherein the antibody is an IgG.

23. The isolated host cell of claim 5 , which is a CHO, VERO, BHK, HeLa, COS, MDCK, HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O, PER.C6, T47D, NS0, CRL7O3O, or HsS78Bst cell.

24. The isolated host cell of claim 9 , wherein the expression vectors are viral vectors.

25. The isolated host cell of claim 24 , wherein the viral vectors are replication defective retroviruses, adenoviruses, adeno-associated viruses, or baculoviruses.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2022
From: PALESE, PETER; KRAMMER, FLORIAN; WOHLBOLD, TEDDY JOHN; GARCIA-SASTRE, ADOLFO
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 060799/0813 →
Continuity (3)
Division 16500628
Provisional Application 62483262 · Apr 7, 2017
Related Publication 20220363736A1 · Nov 17, 2022
Cited By (2)
US 12,545,718 US 12,655,408